Topramezone and Terbuthylazine were first registered in sugarcane fields in China
Recently, Jiner(Qingdao) applied for 28% of TopramezoneTerbuthylazine OD products (Topramezone 2%+ Terbuthylazine 26%) was approved for registration.
The registered crops and control objects are annual weeds in spring corn field and annual weeds in sugarcane field. When controlling annual weeds in sugarcane field, it is recommended to apply 80 ~ 100 ml/mu of spray with 30 ~ 50 kg of water at the 3-5 leaf stage of sugarcane and 2-5 leaf stage of weeds, and use uniform stem and leaf spray once a season at most. This is the first time that China has approved Topramezone and Terbuthylazine for registration in sugarcane fields.
Previously, Topramezone was mainly registered in China for the control of weeds in corn fields, sorghum fields and non-arable land, and Terbuthylazine was mainly registered in China for the control of weeds in corn fields and sorghum fields.
According to GB 2763-2021, the maximum residue limit of Topramezone in corn and fresh corn in China is 0.05 mg/kg (provisional limit), and the maximum residue limit of Terbuthylazine in wheat, corn and fresh corn in China is 0.05, 0.1 and 0.1 mg/kg, respectively. The maximum residue limits of both in sorghum and sugarcane in China have not yet been specified.
2026-07-25
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Flagchem: Topramezone project’s trial production is imminent
-
BSM's Pendimethalin is expected to increase in overseas markets
-
Obesity Drugs Become Pharma’s Most Powerful Growth Engine
-
Smog Becomes a Sales Catalyst as Respiratory Drugs Surge in November
-
Indian Immunologicals Pushes Back on “Fake Vaccine” Claims Amid Global Supply Chain Scrutiny
-
Minoxidil Safety Under Global Review as Infant Exposure Risks Surface
-
Substandard Drug Findings Expose Deep Structural Gaps in Medicine Quality Control
-
Vertex Pushes Gene Therapy Into Younger Children With Blood Disorders
-
Lilly’s Mounjaro Enters China’s State Insurance System
-
A New Obesity Pill Enters the Arena With Double-Digit Weight Loss
Recommend Reading
-
Wegovy Slips on Price While Mounjaro Defends Its Weight-Loss Crown
-
Another Major Coating Manufacturer Acquired by a Central SOE: BNBM Acquires SUNROAD Group for Over RMB 300 Million, Locks in Three-Year Performance Pledge
-
Arkema and ENNEX Forge Global Alliance to Power the Next Generation of Safer, Smarter Battery Separators
-
“Zero Tariff Is Not a Get-Out-of-Jail-Free Card”: Hainan’s Full Customs Closure—Boon or Trap for the Chemical Industry?
-
“Did They Just Buy a Money Printer for ¥288 Million?”: Yip’s Chemical’s Bold Bet on Green Tech—Is This a Genuine Transformation or Just Another Story for the Stock Market?
-
Acetic Acid Market Prices Continue to Rise
-
The FDA Officially Blesses AI for Liver Drug Development
-
After Two Rounds of Price Cuts, the Coke Market Stabilizes in China
-
After Hitting Bottom in 2025, Melamine Strongly Rebounds in China; Can 2026 See a Demand-Driven Turnaround?
-
2025 Crude Oil Market Prices Decline—Can 2026 Bring a Turning Point?